BioSpace News Archive

Engitix Ltd announces the appointment of Sonia Quaratino, M.D., PH.D., to its Board of Directors, as an independent non-executive director.

PUR Biologics, an innovative biotech company, and wholly-owned subsidiary of HippoFi, Inc. (OTC PINK:ORHB), today has unveiled its latest product, PURbonedough™, to further expand its leadership into the burgeoning spine biologics market.

MindBio Therapeutics Corp. is pleased to announce its scientific collaborators have recently published their first Peer Reviewed Paper in Biological Psychiatry, an official journal of Psychiatric Neuroscience and Therapeutics.

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 363 owned and operated outpatient imaging centers, reported financial results for its first quarter of 2023.

Novavax, Inc. announced that its COVID-Influenza Combination, stand-alone influenza and high-dose COVID vaccine candidates all showed a reassuring preliminary safety profile as well as comparable reactogenicity to individual Novavax influenza and COVID vaccine candidates or authorized influenza vaccine comparators.

ImmunoGen, Inc. announced that results from the Phase 3 confirmatory MIRASOL trial evaluating the safety and efficacy of ELAHERE® compared to chemotherapy in patients with folate receptor alpha -positive platinum-resistant ovarian cancer, have been selected for a late-breaking oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting taking place June 2-6, 2023 in Chicago, Illinois.

Voyager Therapeutics, Inc., a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, announced the appointment of George Scangos, Ph.D., to its Board of Directors.

Salipro Biotech AB and DyNAbind GmbH, two leading biotech companies, announced the achievement of a key milestone from their collaboration aimed to revolutionize drug discovery against difficult-to-drug targets.

Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, announced it will participate in a fireside chat at the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day in New York City on Monday, May 15, 2023.

Alkermes plc announced the acceptance of two abstracts related to nemvaleukin alfa, the company’s novel, investigational, engineered interleukin-2 variant immunotherapy, for presentation at the American Society of Clinical Oncology Annual Meeting, taking place in Chicago June 2-6, 2023.